Short Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Increases By 23.7%

Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 713,000 shares, an increase of 23.7% from the January 31st total of 576,400 shares. Based on an average daily volume of 363,700 shares, the days-to-cover ratio is presently 2.0 days. Currently, 27.0% of the company's stock are short sold.

Aligos Therapeutics Stock Performance

Shares of Aligos Therapeutics stock traded down $0.54 during midday trading on Friday, hitting $12.94. The company had a trading volume of 260,296 shares, compared to its average volume of 167,316. The company has a 50 day moving average of $27.25 and a 200 day moving average of $20.49. The stock has a market capitalization of $46.43 million, a P/E ratio of -0.97 and a beta of 2.52. Aligos Therapeutics has a 52-week low of $6.76 and a 52-week high of $46.80.

Hedge Funds Weigh In On Aligos Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of ALGS. Tower Research Capital LLC TRC increased its position in shares of Aligos Therapeutics by 2,073.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 652 shares of the company's stock valued at $26,000 after acquiring an additional 622 shares in the last quarter. AlphaMark Advisors LLC increased its holdings in shares of Aligos Therapeutics by 1,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company's stock worth $44,000 after purchasing an additional 1,000 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Aligos Therapeutics by 19.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company's stock worth $569,000 after purchasing an additional 2,306 shares during the last quarter. Golden State Wealth Management LLC bought a new position in shares of Aligos Therapeutics during the fourth quarter valued at $107,000. Finally, Geode Capital Management LLC boosted its position in shares of Aligos Therapeutics by 13.3% during the fourth quarter. Geode Capital Management LLC now owns 27,253 shares of the company's stock valued at $1,086,000 after buying an additional 3,197 shares during the last quarter. 60.43% of the stock is currently owned by institutional investors.

Remove Ads

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).